Evidence map›Paper›PMID 36332632›Full record

ArticleStem cell reports2022

The monoculture of cord-blood-derived CD34

Mark Jones, Annie Cunningham, Nathan Frank, Dalip Sethi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mark JonesResearch and Development, Terumo Blood and Cell Technologies, Lakewood, CO 80215, USA. Electronic address: mark.jones@terumobct.com.
Annie CunninghamResearch and Development, Terumo Blood and Cell Technologies, Lakewood, CO 80215, USA.
Nathan FrankResearch and Development, Terumo Blood and Cell Technologies, Lakewood, CO 80215, USA.
Dalip SethiResearch and Development, Terumo Blood and Cell Technologies, Lakewood, CO 80215, USA.
Terumo (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte antigen (HLA)-matched cord blood (CB) transplantation is a procedure for the treatment of certain hematological malignancies, hemoglobinopathies, and autoimmune disorders. However, one of the challenges is to provide a sufficient number of T cell-depleted hematopoietic stem and progenitor cells. Currently, only 4%-5% of the CB units stored in CB banks contain enough CD34

Indexed as

CytokinesFetal BloodAntigens, CD34Cell Culture TechniquesCells, CulturedHematopoietic Stem CellsHumansPerfusionStem Cell FactorAntigens, CD34CytokinesStem Cell Factorcord-blood-derived CD34(+) cellsexpansionfibronectin-SDF-1GDNFperfusion membrane bioreactorQuantum system

Identifiers

PMID36332632
PMCPMC9768577
OpenAlexW4308017099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.